.jpg)
Advent Pharmaceuticals (AP) can assist any pharmaceutical company or medical device manufacturer interested in growing revenues by actively pursuing the ever expanding Chinese market through either direct sales to China, licensing opportunities in China or technology transfers to China. The challenge, however, is the SFDA has implemented new regulations requiring foreign companies to navigate through a stringent approval process in China before they can market their drugs or devices in that country. This has significantly raised the barrier for most foreign companies entering China. AP can manage and pilot the entire process from license negotiations all the way through approvals from the SFDA. Advent Pharmaceuticals will also work to obtain exclusive or "favored" distribution status for our client's drugs and devices in China - either directly or through licensing partners.
U.S. FDA approved pharmaceuticals and medical devices have a tremendous advantage in the Chinese marketplace due to a strong bias by the Chinese public for Western products. Advanced Pharmaceuticals is in a unique position to help your company prolong the life cycle of your pharmaceuticals and medical devices as well as increase profitability based on this bias, by obtaining the necessary SFDA approvals in China. AP can also assist your company subsequent to approval by distributing your drugs or devices throughout all of China's provinces.
AP provides a wide range of services to U.S. and international pharmaceutical and medical device companies interested in distributing their products in China. For clients interested in acomplishing this goal directly, Advent Pharmaceuticals, acting as exclusive agent, can handle and submit all of the necessary applications, coordinate the necessary testing\trials and ultimately assist in obtaining SFDA approvals for the desired drugs or devices which we would in turn, market throughout all of China. For clients who what to expand into China, but do not want bear the costs typically associated with drug and device approvals by the SFDA, AP can identify the ideal Chinese licensing partners for the targeted drugs or devices. Additionally, Advent Pharmaceuticals can assit companies interested in pharmaceutical or medical technology transfers to China as well as companies seeking to establish a Chinese operation or joint venture to manufacture drugs or devices in China.
An important component of the Advent Pharmaceuticals team is our partner contract research organizations (CRO's) and service research organizations (SRO's) in China - all of which meet FDA, GLP and OECD guidelines for clinical trials.
The current population in China is over 1,300,000,000 people and by the end of 2010, the PRC government plans to cover 85% of the total population with medical care and prescription drugs. Even at 85% of the population, the potential patient mix still amounts to over 1,100,000,000 people at various ages and different pharmaceutical and medical needs. Now is the perfect time to request a consultation from Advanced Pharmaceuticals!
